IS STAVUDINE.html
LETTERS
Is stavudine worth saving?
To the Editor:
The ultimate goal of HIV therapy in resource-constrained settings must
be to keep as many people alive with the best possible quality of life
using the resources available. The question debated between
Andrieux-Meyer et al.1 and Venter et al.2
,
3
might therefore be: ‘With the resources available, can we keep
more people alive with the best possible quality of life using
stavudine 20 mg bd or tenofovir 300 mg od as standard first line
therapy?’ Quality of life is extremely important but unlikely to
be the overriding factor if budgetary constraints restrict access to
ART and therefore increase mortality. Both groups seem to agree that
tenofovir is superior to stavudine for most patients and that the crux
of the argument is about cost. Venter et al.
describe tenofovir as ‘the gold standard’ and state that
‘these arguments [about the benefits of tenofovir] are likely to
be irrelevant when the cost of medication is considered’.
Andrieux-Meyer et al. acknowledge that ‘the rationale for this [proposed] trial is to lower treatment costs’.
The question of whether stavudine or tenofovir will ultimately save
the most lives within the budget is complex. Many of the variables
change over time and differ between countries. The ‘resources
available’ may even be influenced by the choice of ART regimens
if, for example, a government tries to save money by using inferior but
cheaper drugs. In some settings, the rate-limiting factors for saving
lives may not actually be financial resources to buy medications but a
lack of human resources or logistic challenges. Despite these
complexities, it is important that each side provides as clear a
picture as possible. In addition to cost-effectiveness estimates, we
need absolute cost estimates for competing regimens including the
estimated minimum cost of tenofovir once costs are driven primarily by
raw materials. We need estimates of the number of patients requiring
ART over time, and we need to know how much funding is available. In
particular, we need to know how the recent cuts to funding from donors
such as the Global Fund will affect the provision of ART in different
countries. Without such figures, any discussion about drugs in phase II
trials that have a high attrition rate and long time delay before
affordability is frankly irrelevant.
Venter et al.
have conceded that 2 years may be too short to show differences between
the groups, and it will be vital to motivate for lengthening the trial
if non-inferiority is shown at 2 years. Upon completion of the trial,
it would seem sensible to use the cheaper option if non-inferiority is
shown. However, even if stavudine is not non-inferior (i.e. is
inferior), it still might be preferred in some settings if the
alternative is running out of money and restricting access to ART. We
commonly use inferior treatments owing to cost constraints; just one
example is the use of amphoteracin B monotherapy to treat cryptococcal
meningitis rather than the superior but more expensive combination of
liposomal amphoteracin B and flucytosine. Activists will argue that we
should continue to lobby for increases in funding and reductions in
drug cost. Of course we should, but we must also be mindful to look at
the problem through the eyes of future patients. They will not thank us
if our lobbying efforts fail to prevent ART rationing owing to
shortfalls in funding.
It is clear that both sides of the debate have the best interests of
patients in mind. To make an informed decision on the merits of
trialling stavudine against tenofovir in the Southern African context,
we need a clearer description of the costs of each strategy and the
likely available resources. In short, we need to know whether choosing
tenofovir over stavudine in first-line therapy is likely to lead to
restricted access to care in some settings.
Tom H Boyles
Division of Infectious Diseases & HIV Medicine
Department of Medicine
Groote Schuur Hospital and University of Cape Town
REFERENCES
1. Andrieux-Meyer I, Clayden P, Collins S, et al. Why it’s time
to say goodbye to stavudine... everywhere. Southern African Journal of
HIV Medicine 2012;13:17-19.
1. Andrieux-Meyer I, Clayden P, Collins S, et al. Why it’s time
to say goodbye to stavudine... everywhere. Southern African Journal of
HIV Medicine 2012;13:17-19.
2. Innes S, Cotton M, Venter F. Why should we still care about the
stavudine dose? Southern African Journal of HIV Medicine 2011;12:14-15.
2. Innes S, Cotton M, Venter F. Why should we still care about the
stavudine dose? Southern African Journal of HIV Medicine 2011;12:14-15.
3. Venter F, Innes S, Cotton M. Low-dose stavudine trials: a public
health priority for developing countries. Southern African Journal of
HIV Medicine 2012;13:20-21.
3. Venter F, Innes S, Cotton M. Low-dose stavudine trials: a public
health priority for developing countries. Southern African Journal of
HIV Medicine 2012;13:20-21.